What’s Driving Growth in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market? Insights into Key Trends and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the paroxysmal nocturnal hemoglobinuria (pnh) market?
The paroxysmal nocturnal hemoglobinuria (PNH) market has expanded significantly, forecasted to grow from $4.24 billion in 2024 to $4.68 billion in 2025, at a CAGR of 10.4%. Growth factors include increasing demand for PNH treatment, rising disposable incomes, government initiatives, and greater healthcare spending.
What will be the paroxysmal nocturnal hemoglobinuria (pnh) market size in the future?
The paroxysmal nocturnal hemoglobinuria (PNH) market is expected to expand strongly, reaching $6.69 billion in 2029 at a CAGR of 9.3%. Growth will be driven by an aging population, rising demand for self-administered treatments, improved healthcare access, increasing prevalence of comorbidities, and advancements in personalized medicine. Major trends include the adoption of digital health technologies, innovations in treatment, the rise of gene therapy, and early intervention strategies.
Get your paroxysmal nocturnal hemoglobinuria (pnh) market report here!
What main drivers are fueling expansion in the paroxysmal nocturnal hemoglobinuria (pnh) market?
The increasing prevalence of eye-related diseases is expected to drive the panuveitis treatment market. Ocular diseases impact vision and overall eye health, necessitating treatments to reduce inflammation, prevent complications, and enhance patient quality of life. For example, in December 2022, the Centers for Disease Control and Prevention (CDC) reported that 20.5 million Americans over 40 had at least one cataract, with projections indicating that approximately 30 million individuals will be affected by cataract disease by 2028. Thus, the growing incidence of eye diseases is fueling the panuveitis treatment market.
What key areas define the segmentation of the global paroxysmal nocturnal hemoglobinuria (pnh) market?
The paroxysmal nocturnal hemoglobinuria (PNH) market covered in this report is segmented –
1) By Treatment Type: Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types
2) By Diagnosis Type: Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types
3) By End Use: Hospitals, Clinics, Other End Users
Subsegments:
1) By Medications: Eculizumab, Ravulizumab, Complement Inhibitors, Supportive Care Medications
2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation, Autologous Stem Cell transplantation
3) By Blood Transfusion: Red blood Cell Transfusion, Platelet Transfusion, Fresh Frozen Plasma Transfusion
4) By Immunosuppressive Therapy: Corticosteroids, Azathioprine, Cyclophosphamide, Mycophenolate Mofetil
5) By Other Treatment Types: Supportive Therapies, Management Of Complications
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12936&type=smp
Who are the dominant players expanding their reach in the paroxysmal nocturnal hemoglobinuria (pnh) market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd., Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.
How are evolving market trends shaping paroxysmal nocturnal hemoglobinuria (pnh) Strategies?
Key players in the Paroxysmal Nocturnal Hemoglobinuria (PNH) field are striving to maintain their market hold by creating novel drugs and therapeutic strategies, such as injectable C5 inhibitors for PNH treatment. Injectable C5 inhibitors, acting as monoclonal antibodies, hinder the activity of complement component C5, thus mitigating inflammation and tissue devastation in autoimmune disorders, including PNH. For example, Chugai Pharmaceutical Co., a pharmaceutical firm based in Japan, earned a primacy appraisal endorsement from the National Medical Products Administration (NMPA) of China in February 2024 for treating PNH. This accomplishment attests China to be the first nation to sanction PIASKY before any other primary marketplaces, consequently setting forth its entry into the National Reimbursement Drug List (NRDL) discussions within the same annum. With PNH being identified as a rare disorder affecting approximately 12,740 individuals in China, the market holds considerable potential.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12936
Which regions are emerging as leaders in the paroxysmal nocturnal hemoglobinuria (pnh) market?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2024. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Acute Myeloid Leukemia Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report
Cancer Clinical Decision Tools Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report
Leukemia Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
